Following an intensive selection process through a dedicated sector-specific jury, eleven European companies are laureates of the 2019 roadshow of the “Start.Smart.Global” programme. They will benefit from a unique training programme including 1 week to Japan and 1 week to Korea.
The programme will enable the start-ups & SMEs to enter two recognised Asian innovation hubs which can act as major stepping stones into the Asian market and initiate significant collaboration opportunities with qualified stakeholders. Japan has the world’s 2nd largest healthcare market and ranks amongst Europe’s top 5 pharmaceutical trading partners. And South Korea is nurturing a culture of innovation and attractive regulatory environment to place itself in the top ranking of global health care hubs
The programme will run over 2019 and is set up as follow:
- An intensive on-site training will be carried out on 8-11 July in Paris for Korea and on 9-12 September in Martinsried/Munich for Japan. Focus of the workshops is a 2-day culture training, followed by two days of business training, comprising of peer-learning with companies already successfully operating in the target markets in the relevant sectors. The training is sector-specific and targets the challenging Japanese and Korean business environments: regulatories and reimbursement for health products/services, access to agents and distributors with access to the appropriate customer networks, access to funding and financing opportunities, language and cultural complexities, different business conventions, understanding of market needs and competition.
- A 15-day immersion roadshow in October in Japan and Korea to meet the local players (support structures, KOLs and potential partners), gain first visibility and traction and understand the local innovation trends and healthcare market access opportunities;
- Post-visit evaluations to optimize the individual market entry strategies.
The target participants in the GoGlobal programmes are start-ups and SMEs – companies who already offer a product, started to sell, or who are in the last stage of their certification process. They have the ambition to expand on the two Asian markets within a year. The companies also fit to the EIT Health thematic scope: “Healthy living, Active Ageing, Improved Health care.”
The following 11 European companies were selected (more information about the companies and the project: www.bio-m.org/start.smart.global)
- Biopromic AB – Sweden
- Biovista Inc – Greece
- Eukarÿs – France
- Ibidi GmbH – Germany
- Mecuris GmbH – Germany
- NextCell Pharma AB – Sweden
- Oncgnostics GmbH – Germany
- Oncodesign SA – France
- Par´Immune – France
- Scinus Cell Expension B.V - The Netherlands
- TherapySelect Dr. Frank Kischkel – Germany
BioM (lead): BioM is a globally experienced European life science cluster located in Munich, Germany. BioM provides many services for small and medium sized enterprises in life sciences resident in Bavaria who intend to internationalize their business. BioM provides support in finding financing and cooperating partners anywhere abroad, in particular for R&D or for licensing. It helps developing new markets in European and non-European countries.
BioM presents the Bavarian biotechnological cluster at many trade fairs and conferences at home and abroad.
Medicen Paris Region (partner): Medicen Paris Region is a competitiveness cluster for innovative health technologies, with national and international scope. With more than 450 companies, research centres, universities, hospitals and local authorities as members, it aims to position the Paris region as Europe’s leading healthcare cluster. It focuses on five strategic areas: biological diagnostics, diagnostic and interventional imaging, innovative biotherapies, digital health and technotherapies.